[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100643609","phase-2-a-study-to-assess-the-correct-dose-safety-and-efficacy-of-empasiprubart-in-adolescent-participants-aged-12-to-less-than-18-years-with-chronic-inflammatory-demyelinating-polyradiculoneuropathy-100643609",false,"NCT07638566","A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","emlight","Inclusion Criteria:\n\n* Is aged 12 to \\\u003C18 years.\n* Meets criteria for CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021).\n* Has a diagnosis of either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP.\n\nExclusion Criteria:\n\n* Possible CIDP based on EAN\u002FPNS Task Force CIDP guidelines, second revision (2021).\n* Sensory CIDP (including sensory-predominant CIDP).\n* Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP, or that puts the participant at undue risk.\n* Prior use of other long-acting immunomodulatory treatment.","ALL","12 Years","17 Years",{"count":21,"type":22},6,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims to evaluate if empasiprubart may work and how safe it is for the use in children living with CIDP.\n\nThe study consists of an open label treatment phase where participants will receive empasiprubart for up to 27 months approximately. After the final dose of empasiprubart, participants will enter a safety follow-up period for up to 14 months approximately.\n\nThe overall study duration for each participant is up to 43 months.\n\nMore information can be found here: clinicaltrials.argenx.com\u002Femlight",[29,30,31,32],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)","CIDP","Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","NOT_YET_RECRUITING","2026-06-05",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":22},"2026-09",{"date":41,"type":22},"2031-08",{"name":43,"class":44},"argenx","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100577416","phase-2-a-study-of-tak-411-in-adults-with-chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp-100577416","NCT06798012","A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)","CASCA","Key Inclusion Criteria\n\n1. The participant is at least 18 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).\n2. The participant has a body weight of less than or equal to (\\\u003C=) 150 kilogram (kg).\n3. The participant has a documented diagnosis of typical CIDP, as confirmed by a neurologist specializing\u002Fexperienced in neuromuscular diseases and consistent with the European Academy of Neurology\u002FPeripheral Nerve Society (EAN\u002FPNS) 2021 criteria.\n4. The participant has responded to IgG treatment in the past (documented partial or complete resolution of neurological symptoms and deficits).\n5. The participant has had disease activation within 24 months before screening, as documented in medical records and in the opinion of the investigator, defined as one of the following:\n\n   1. Clinically meaningful deterioration of symptoms on interruption or dose reduction of IgG treatment.\n   2. Clinically meaningful deterioration of symptoms requiring IgG treatment dose increase with subsequent clinical improvement.\n   3. Clinically meaningful deterioration of symptoms at the end of IgG treatment dose interval with improvement after next dose administration.\n6. The participant is on a stable dose of immunoglobulin treatment intravenously (IGIV) treatment, (within the dose range of 0.4 to 2.4 grams per kilogram \\[g\u002Fkg\\] every 2 to 6 weeks \\[inclusive\\]). A stable dose is defined as no change greater than 10 percentage (%) in frequency or dose of IGIV therapy within the 3 months before and throughout screening.\n7. The participant has an INCAT score between 0 and 7 (inclusive) at screening.\n\nKey Exclusion Criteria\n\n1. The participant has a documented diagnosis of a CIDP variant per EAN\u002FPNS 2021 criteria.\n2. The participant has any neuropathy of other causes, including the following:\n\n   1. Hereditary demyelinating neuropathies, such as hereditary sensory and motor neuropathy, Charcot-Marie-Tooth disease, and hereditary sensory and autonomic neuropathies.\n   2. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and nondiabetic lumbosacral radiculoplexus neuropathy, lymphoma, amyloidosis.\n   3. Multifocal motor neuropathy.\n   4. Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy.\n   5. Diabetic peripheral neuropathy.\n3. The participant has any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or that may interfere with assessment of CIDP or outcome measures, including (but not limited to) multiple sclerosis, arthritis, stroke, and Parkinson's disease.\n4. The participant is required to take or has taken either of the following for treatment of CIDP:\n\n   1. Immunomodulatory\u002Fimmunosuppressive agents (except IGIV) that include, but are not limited to, complement inhibitors, efgartigimod, and chemotherapeutic drugs, within 3 months or 5 half-lives, whichever is longer, of screening.\n   2. B-cell affecting biologics (e.g. rituximab) within 6 months of screening.\n\n   Note: Participants on a long-term, stable dosing regimen of certain immunomodulatory agents (eg, hydroxychloroquine) for any disease other than CIDP may be eligible, provided the dose regimen has been stable for 3 months before screening and is expected to remain stable throughout the study.\n5. The participant has undergone plasma exchange within 3 months of screening.\n6. The participant has a history of malignancy with less than 2 years of complete remission before screening, or active malignancy requiring chemotherapy and\u002For radiotherapy.\n\n   Note: Participants with adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment are eligible.\n7. The participant has experienced deep vein thrombosis or arterial thromboembolic events (example, cerebrovascular accident, pulmonary embolism) within 12 months of screening.\n8. The participant has any medical condition, laboratory finding, or physical examination finding that precludes participation or with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the study or place the participant at undue medical risk.\n9. The participant has participated in another clinical study involving an IP or investigational device within 30 days before screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.","18 Years",{"count":55,"type":22},36,[25],"CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG).\n\nTAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP.\n\nThe main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial.\n\nParticipants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose.\n\nDuring the study, participants may visit their study clinic up to approximately 21 times.",[32],[60],"Drug Therapy","RECRUITING","2026-04-20",{"date":64,"type":37},"2026-04-23",{"date":66,"type":37},"2025-05-14",{"date":68,"type":22},"2028-06-08",{"name":70,"class":44},"Takeda",20,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100573520","phase-3-a-study-to-compare-tak-881-and-hyqvia-in-adults-with-chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp-100573520","NCT06747351","A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Inclusion Criteria\n\n* Participant is willing and able to understand and fully comply with trial procedures and requirements, in the opinion of the investigator.\n* Participant has provided informed consent (that is, in writing, documented via a signed and dated informed consent Form \\[ICF\\]) and any required privacy authorization before the initiation of any trial procedures.\n* Participant has a documented diagnosis of CIDP or possible CIDP, as confirmed by a neurologist specializing\u002Fexperienced in neuromuscular diseases and consistent with the European Federation of Neurological Societies\u002FPeripheral Nerve Society (EFNS\u002FPNS) 2021 criteria.\n* Participant has responded to IgG treatment in the past (documented partial or complete resolution of neurological symptoms and deficits).\n* Participant is on a stable, pretrial treatment with IGIV, cIGSC, or HYQVIA (also known as TAK-771 in Japan) within the dose range equivalent to a cumulative monthly IgG dose of 0.4 to 2.4 grams per kilogram (g\u002Fkg) body weight (BW) (inclusive) administered for at least 12 weeks before screening. The dosing interval of IGIV treatment must be between 2 and 6 weeks (inclusive). The dosing interval must be weekly or biweekly for cIGSC dosing and less than or equal (\\\u003C=) to 6 weeks for HYQVIA dosing. Prior to screening, variations in the dosing interval of up to +-7 days or monthly dose amount of up to +-20 percentage (%) between the participant's pretrial IgG infusions are acceptable.\n* Participant has an INCAT disability score between 0 and 7 (inclusive). Participants will be eligible if one of the below eligibility criteria are met:\n\n  1. Screening INCAT disability score of between 3 and 7 inclusive.\n  2. Screening INCAT disability score of 2 (both points are from lower extremities).\n  3. Screening INCAT disability score of 2 (both points are not from lower extremities) AND has at least a score of 2 or greater documented in the medical record before screening. If a score was greater than 2 documented in the medical record before screening at least 2 points must be from lower extremities.\n  4. Screening INCAT disability score of 0 or 1 AND has at least a score of 2 or greater (both from lower extremities) documented in the medical record before screening, at least 2 points must be from lower extremities.\n* If a participant has the potential to become pregnant, they must have a negative pregnancy test at screening and agree to employ a highly effective contraceptive measure throughout the course of the trial and for at least 30 days after the last administration of the investigational medical product (IMP).\n\nExclusion Criteria\n\n* Participant with documented diagnosis of focal, multifocal, distal, or sensory CIDP, or possible focal, multifocal, distal, or sensory CIDP per the EFNS\u002FPNS 2021 criteria.\n* Participant has any neuropathy of other causes, including:\n\n  1. Hereditary demyelinating neuropathies, such as hereditary sensory and motor neuropathy (HSMN), Charcot-Marie-Tooth (CMT) disease, and hereditary sensory and autonomic neuropathies (HSANs).\n  2. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy, lymphoma, amyloidosis.\n  3. Multifocal motor neuropathy (MMN).\n  4. Drug, biologic, chemotherapy, or toxin-induced peripheral neuropathy.\n* Participant has any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or which may interfere with assessment of CIDP or outcome measures, including (but not limited to) multiple sclerosis, arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy.\n\nNote: Participants with clinically diagnosed diabetes mellitus who do not have diabetic peripheral neuropathy and who have adequate glycemic control with hemoglobin A1c \\[HbA1c\\] level of less than (\\\u003C) 7.5% at screening will be eligible for the trial, provided the electrodiagnostic criteria are consistent with the diagnosis of CIDP or possible CIDP consistent with the EFNS\u002FPNS 2021 criteria and the participant agrees to maintain adequate glycemic control.\n\n* Participant is required to take or has taken immunomodulatory\u002Fimmunosuppressive agents (except IGIV, cIGSC, or fIGSC) that include but are not limited to specific complement inhibitors, rituximab, neonatal FC receptor inhibitors (e.g. efgartigimod), and chemotherapeutic drugs, within 6 months of screening.\n* Participant is required to take or has taken long-term systemic corticosteroids defined as dosages greater than (\\>) 20 milligrams per day (mg\u002Fday) prednisone-equivalent for \\>30 days within 3 months of screening.\n\nNote: Participants using short-pulse dose corticosteroid course and oral daily corticosteroids \\\u003C= 20 mg\u002Fday prednisone-equivalent are allowed.\n\n* Participant has undergone plasma exchange within 3 months before screening.\n* Participant has immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with a high titer of antibody to myelin-associated glycoprotein.\n* Participant has immunoglobulin A (IgA) deficiency (IgA \\\u003C0.07 grams per liter \\[g\u002FL\\]) associated with known anti-IgA antibodies and a history of hypersensitivity to human immunoglobulin treatment.\n* Participant has a condition(s) which could alter protein catabolism and\u002For IgG use (for example \\[eg.\\] protein losing enteropathies, and nephrotic syndrome).\n* Participant has a history or clinical manifestations of chronic kidney disease, or glomerular filtration rate of \\\u003C30 milliliters per minute per 1.73 square meter (mL\u002Fmin\u002F1.73 m\\^2) estimated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at the time of screening.\n* Participant has a history of malignancy with less than 2 years of complete remission before screening, or active malignancy requiring chemotherapy and\u002For radiotherapy.\n\nNote: Participants with adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment are eligible.\n\n* Participant has congestive heart failure (New York Heart Association class III\u002FIV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension (defined as diastolic blood pressure \\>100 millimeters of mercury (mm Hg) and\u002For systolic blood pressure \\>160 mm Hg during the screening epoch confirmed on 2 measures \\>30 minutes apart).\n* Participant has an acquired or inherited thrombophilic disorder, such as protein C deficiency, protein S deficiency, antithrombin deficiency, and primary antiphospholipid antibody syndrome.\n* Participant has a history of deep vein thrombosis or arterial thromboembolic events (eg, cerebrovascular accident, pulmonary embolism) within 12 months before screening.\n* Participant has any medical condition, laboratory finding, or physical examination finding that precludes participation or with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial or place the participant at undue medical risk.\n* Participant has a known history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV, IGSC, and\u002For immune serum globulin infusions.\n* Participant has a known systemic hypersensitivity to any of the excipients of TAK-881\u002FHYQVIA in accordance with the Investigator's Brochure (IB)\u002Fpackage insert\u002FSummary of Product Characteristics (SmPC).\n* Participant has a known systemic hypersensitivity to hyaluronidase or rHuPH20.\n* Participant has a known history of positive result for or is positive at screening for one or more of the following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for hepatitis C virus (HCV), PCR for Human Immunodeficiency Virus (HIV) Type 1 and Type 2.\n\nNote: Cured participants with a history of hepatitis C infection who have a negative PCR test at screening are eligible.\n\n* Participant has clinically significant anemia that precludes repeated blood sampling during the trial, or hemoglobin level of \\\u003C10.0 grams per deciliter (g\u002FdL) at the time of screening.\n* Participant has any of the following laboratory values at screening:\n\n  1. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\>2.5\\*upper limit of normal (ULN).\n  2. Platelet count \\\u003C100,000 cells per microliter (cells\u002FµL).\n  3. Absolute neutrophil count \\\u003C1000 cells\u002FµL.\n* If female, the participant is pregnant or lactating at the time of screening.\n* Participant has participated in another clinical trial involving an IMP or investigational device within 12 weeks or 5 half-lives, whichever is longer, before enrollment (except for participants rolling over from the Japan study TAK-771-3002) or is scheduled to participate in another clinical trial involving an IMP or investigational device during the course of this trial.\n* Participant is a trial site employee, an immediate family member (eg, spouse, parent, child, sibling), or is in a dependent relationship with a trial site employee who is involved in conduct of this trial or may consent under duress.",{"count":80,"type":22},59,[26],"The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP.\n\nThe participants who are already receiving intravenous immunoglobulin G (IGIV), conventional subcutaneous intravenous immunoglobulin G (cIGSC), or HYQVIA will be treated with the same dose equivalent as their prior IG treatment with HYQVIA for 20 weeks followed by TAK-881 for 24 weeks.\n\nParticipants will need to visit the clinic every 3 or 4 weeks until they enter the extension phase. In the extension phase, home infusions are allowed, and visits will occur between every 12 weeks and 24 weeks.",[32],[85,86,29],"Immunoglobulin","facilitated subcutaneous , Immunoglobulin;","2026-01-16",{"date":89,"type":37},"2026-01-20",{"date":91,"type":37},"2025-05-06",{"date":93,"type":22},"2028-06-25",{"name":70,"class":44},52,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100557434","a-study-of-hyqvia-in-adults-with-chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp-in-routine-clinical-care-100557434","NCT06538064","A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care","A Global Real-World Study to Assess HyQvia Use and Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Switching to HyQvia","HYbISCUE","Inclusion Criteria:\n\n* Participants aged 18 years or older.\n* Investigator-confirmed documented diagnosis of CIDP of any type (e.g., typical, multifocal, focal, motor, sensory, or distal) according to the revised European Academy of Neurology and Peripheral Nerve Society (EAN\u002FPNS) 2021 guidelines on the diagnosis and treatment of CIDP.\n* Participants must currently have a stable disease course (as per physician judgment) for at least 12 weeks.\n* Is considered a new user or current user of HyQvia-\n\n  * New users (Cohort A) are participants on a CIDP treatment as of the date of enrollment, who intend to switch to HyQvia within 6 weeks after enrollment.\n  * Current users (Cohort B) are participants on HyQvia as of the date of enrollment, who switched to HyQvia within the 6 weeks preceding the date of enrollment (the 6-week window may be extended depending on the recruitment progress).\n* Has provided written informed consent (for the main study).\n* Participant is willing to comply with the protocol requirement of non-standard of care (non-SOC) assessments (e.g., adjusted inflammatory neuropathy cause and treatment (INCAT) assessment).\n* Participants must be able to communicate fluently in their local language (if they participate in the optional qualitative participant interview \\[sub-study\\].\n\nExclusion Criteria:\n\n* Had any HyQvia use, defined as\n\n  * any record of HyQvia use prior to enrollment for new users of HyQvia (Cohort A), and\n  * any record of HyQvia use more than 6 weeks preceding the enrollment date (the 6-week window may be extended depending on the recruitment progress) for current users of HyQvia (Cohort B).\n* Without any prior treatment for CIDP.\n* Pregnant or breastfeeding.\n* Participants with known hypersensitivity to any component of HyQvia.\n* Has participated in an interventional clinical study within 30 days prior to enrollment or was scheduled to participate in an interventional clinical study during this study.\n* Has had major surgery within 12 weeks prior to enrollment, or has surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgeries.\n* Received induction treatment for CIDP during the past 12 weeks.\n* Participant is identified by the investigator as being unable or unwilling to cooperate with the study procedures.\n* (Cohort A) only: Participants who do not initiate HyQvia treatment within 6 weeks after enrollment.",{"count":105,"type":22},30,"OBSERVATIONAL","The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are with HyQvia and their previous treatment, how their work productivity and activity is impacted and learn about their CIDP signs and symptoms. Other aims are to collect information on any medical problems or side effects during the treatment with HyQvia, learn how effective treatment of CIDP with HyQvia is and understand details on the use of HyQvia in standard clinical routine as well on the need for healthcare intervention (such as emergency room visits or hospital visits or stays).\n\nDuring the study, data will be collected from medical records already available, interviews with participants at study start and study completion and via questionnaires completed by participants.\n\nParticipants will be treated as per the doctor's or the clinic's routine.",[32],"2025-11-18",{"date":111,"type":37},"2025-11-21",{"date":113,"type":37},"2025-04-29",{"date":115,"type":22},"2027-08-17",{"name":70,"class":44},15]